Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder

Hui-Hua Chang, Po-See Chen, Tzu-Yun Wang, Sheng Yu Lee, Shiou Lan Chen, San Yuan Huang, Jau Shyong Hong, Yen-Kuang Yang, Ru-Band Lu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Balance in the immune system plays roles in bipolar disorder (BD) and its metabolic co-morbidities. Memantine is an NMDA receptor antagonist with anti-inflammatory effects. However, the effects of memantine adjunct treatment on metabolic status of BD are unclear. Methods During the 12 weeks period, a total of 191 BD patients were enrolled and split into valproate (VPA) + placebo and VPA + memantine (5 mg/day) arms. The fasting plasma levels of high-sensitivity C-reactive protein (CRP) and metabolic indices were assessed. BD patients were stratified according to their initial CRP level. Results A cut-off value of initial CRP level of 2322 ng/mL discriminated the waist circumference in these BD patients after 12-week VPA treatment. In the high CRP (> 2322 ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. However, analysis of the low CRP group did not showed the effect. Limitations We recruited BD patients in depressed states and the sample size was relative small. The effects of the fixed dose of memantine on metabolic indices were 12-week follow up in BD patients treated with VPA. Conclusions BD patients with high initial CRP levels receiving memantine adjunct treatment have a reduced risk of inflammation and metabolic imbalance. Prospective studies are needed to confirm the long-term outcome for memantine adjunct therapy in BD patients.

Original languageEnglish
Pages (from-to)151-157
Number of pages7
JournalJournal of Affective Disorders
Volume221
DOIs
Publication statusPublished - 2017 Oct 15

Fingerprint

Memantine
Bipolar Disorder
C-Reactive Protein
Valproic Acid
Lipids
Waist Circumference
Placebos
Therapeutics
N-Methyl-D-Aspartate Receptors
Sample Size
Immune System
Fasting
Anti-Inflammatory Agents
Cholesterol
Prospective Studies
Inflammation
Morbidity

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Chang, Hui-Hua ; Chen, Po-See ; Wang, Tzu-Yun ; Lee, Sheng Yu ; Chen, Shiou Lan ; Huang, San Yuan ; Hong, Jau Shyong ; Yang, Yen-Kuang ; Lu, Ru-Band. / Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. In: Journal of Affective Disorders. 2017 ; Vol. 221. pp. 151-157.
@article{8e826d3e55464511bc40dd13def509fe,
title = "Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder",
abstract = "Background Balance in the immune system plays roles in bipolar disorder (BD) and its metabolic co-morbidities. Memantine is an NMDA receptor antagonist with anti-inflammatory effects. However, the effects of memantine adjunct treatment on metabolic status of BD are unclear. Methods During the 12 weeks period, a total of 191 BD patients were enrolled and split into valproate (VPA) + placebo and VPA + memantine (5 mg/day) arms. The fasting plasma levels of high-sensitivity C-reactive protein (CRP) and metabolic indices were assessed. BD patients were stratified according to their initial CRP level. Results A cut-off value of initial CRP level of 2322 ng/mL discriminated the waist circumference in these BD patients after 12-week VPA treatment. In the high CRP (> 2322 ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. However, analysis of the low CRP group did not showed the effect. Limitations We recruited BD patients in depressed states and the sample size was relative small. The effects of the fixed dose of memantine on metabolic indices were 12-week follow up in BD patients treated with VPA. Conclusions BD patients with high initial CRP levels receiving memantine adjunct treatment have a reduced risk of inflammation and metabolic imbalance. Prospective studies are needed to confirm the long-term outcome for memantine adjunct therapy in BD patients.",
author = "Hui-Hua Chang and Po-See Chen and Tzu-Yun Wang and Lee, {Sheng Yu} and Chen, {Shiou Lan} and Huang, {San Yuan} and Hong, {Jau Shyong} and Yen-Kuang Yang and Ru-Band Lu",
year = "2017",
month = "10",
day = "15",
doi = "10.1016/j.jad.2017.05.052",
language = "English",
volume = "221",
pages = "151--157",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. / Chang, Hui-Hua; Chen, Po-See; Wang, Tzu-Yun; Lee, Sheng Yu; Chen, Shiou Lan; Huang, San Yuan; Hong, Jau Shyong; Yang, Yen-Kuang; Lu, Ru-Band.

In: Journal of Affective Disorders, Vol. 221, 15.10.2017, p. 151-157.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder

AU - Chang, Hui-Hua

AU - Chen, Po-See

AU - Wang, Tzu-Yun

AU - Lee, Sheng Yu

AU - Chen, Shiou Lan

AU - Huang, San Yuan

AU - Hong, Jau Shyong

AU - Yang, Yen-Kuang

AU - Lu, Ru-Band

PY - 2017/10/15

Y1 - 2017/10/15

N2 - Background Balance in the immune system plays roles in bipolar disorder (BD) and its metabolic co-morbidities. Memantine is an NMDA receptor antagonist with anti-inflammatory effects. However, the effects of memantine adjunct treatment on metabolic status of BD are unclear. Methods During the 12 weeks period, a total of 191 BD patients were enrolled and split into valproate (VPA) + placebo and VPA + memantine (5 mg/day) arms. The fasting plasma levels of high-sensitivity C-reactive protein (CRP) and metabolic indices were assessed. BD patients were stratified according to their initial CRP level. Results A cut-off value of initial CRP level of 2322 ng/mL discriminated the waist circumference in these BD patients after 12-week VPA treatment. In the high CRP (> 2322 ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. However, analysis of the low CRP group did not showed the effect. Limitations We recruited BD patients in depressed states and the sample size was relative small. The effects of the fixed dose of memantine on metabolic indices were 12-week follow up in BD patients treated with VPA. Conclusions BD patients with high initial CRP levels receiving memantine adjunct treatment have a reduced risk of inflammation and metabolic imbalance. Prospective studies are needed to confirm the long-term outcome for memantine adjunct therapy in BD patients.

AB - Background Balance in the immune system plays roles in bipolar disorder (BD) and its metabolic co-morbidities. Memantine is an NMDA receptor antagonist with anti-inflammatory effects. However, the effects of memantine adjunct treatment on metabolic status of BD are unclear. Methods During the 12 weeks period, a total of 191 BD patients were enrolled and split into valproate (VPA) + placebo and VPA + memantine (5 mg/day) arms. The fasting plasma levels of high-sensitivity C-reactive protein (CRP) and metabolic indices were assessed. BD patients were stratified according to their initial CRP level. Results A cut-off value of initial CRP level of 2322 ng/mL discriminated the waist circumference in these BD patients after 12-week VPA treatment. In the high CRP (> 2322 ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. However, analysis of the low CRP group did not showed the effect. Limitations We recruited BD patients in depressed states and the sample size was relative small. The effects of the fixed dose of memantine on metabolic indices were 12-week follow up in BD patients treated with VPA. Conclusions BD patients with high initial CRP levels receiving memantine adjunct treatment have a reduced risk of inflammation and metabolic imbalance. Prospective studies are needed to confirm the long-term outcome for memantine adjunct therapy in BD patients.

UR - http://www.scopus.com/inward/record.url?scp=85021106555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021106555&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2017.05.052

DO - 10.1016/j.jad.2017.05.052

M3 - Article

C2 - 28646711

AN - SCOPUS:85021106555

VL - 221

SP - 151

EP - 157

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -